Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vyne Therapeutics Inc (VYNE)
:VYNE
Holding VYNE?
Track your performance easily
VYNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.57 - $4.30
Previous CloseN/A
Volume117.27K
Average Volume (3M)129.89K
Market Cap
$38.06M
Enterprise Value$9.95M
Total Cash (Recent Filing)$30.91M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Feb 27, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding14,751,433
10 Day Avg. Volume168,782
30 Day Avg. Volume129,887
Standard Deviation0.25
R-Squared0.08
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)77.20
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue21.09
Enterprise Value/Gross Profit24.89
Enterprise Value/Ebitda-0.26
Forecast
1Y Price Target
$6.19Price Target Upside139.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
VYNE Therapeutics News
PremiumCompany Announcements
VYNE Therapeutics Sees Strong Shareholder Support for Growth
PremiumCompany Announcements
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024
Options Prices
Currently, No data available
---
Ownership Overview
11.25% Insiders
5.61% Mutual Funds
34.35% Other Institutional Investors
45.33% Public Companies and Individual Investors
VYNE FAQ
What was Vyne Therapeutics Inc’s price range in the past 12 months?
Vyne Therapeutics Inc lowest stock price was $1.57 and its highest was $4.30 in the past 12 months.
What is Vyne Therapeutics Inc’s market cap?
Vyne Therapeutics Inc’s market cap is $38.06M.
When is Vyne Therapeutics Inc’s upcoming earnings report date?
Vyne Therapeutics Inc’s upcoming earnings report date is Feb 27, 2025 which is in 40 days.
How were Vyne Therapeutics Inc’s earnings last quarter?
Vyne Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.235 by -$0.055.
Is Vyne Therapeutics Inc overvalued?
According to Wall Street analysts Vyne Therapeutics Inc’s price is currently Undervalued.
Does Vyne Therapeutics Inc pay dividends?
Vyne Therapeutics Inc does not currently pay dividends.
What is Vyne Therapeutics Inc’s EPS estimate?
Vyne Therapeutics Inc’s EPS estimate is -0.3.
How many shares outstanding does Vyne Therapeutics Inc have?
Vyne Therapeutics Inc has 14,751,433 shares outstanding.
What happened to Vyne Therapeutics Inc’s price movement after its last earnings report?
Vyne Therapeutics Inc reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.235. Following the earnings report the stock price went up 0.958%.
Which hedge fund is a major shareholder of Vyne Therapeutics Inc?
Currently, no hedge funds are holding shares in VYNE
---
VYNE Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.19 (139.92% Upside)
$6.19 (139.92% Upside)
Insider Transactions
Bought Shares
Worth $43.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.67%
12-Months-Change
Fundamentals
Return on Equity
-90.47%
Trailing 12-Months
Asset Growth
295.48%
Trailing 12-Months
Company Description
Vyne Therapeutics Inc
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
---
VYNE Stock 12 Month Forecast
Average Price Target
$6.19
▲(139.92% Upside)
Technical Analysis
AnaptysBio
―
Oragenics
―
Bioxcel Therapeutics
―
Eloxx Pharmaceuticals
―
Ionis Pharmaceuticals
―
Best Analysts Covering VYNE
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+30.10%
reiterated a buy rating 13 days ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +30.10% per trade.
---